Mangoceuticals' Strategic Equity Agreements
Mangoceuticals, Inc., a health services company based in Texas, has taken a strategic step forward by entering agreements with consulting firms in exchange for equity. Trading on NASDAQ as MGRX, the company recently revealed these arrangements in a filing that highlights its innovative approach to securing essential services.
Consulting Agreement with Veritas
In its ongoing efforts to enhance its investor relations and business advisory capabilities, Mangoceuticals signed a Consulting Agreement with Veritas Consulting Group, Inc. This agreement involves the issuance of 150,000 shares of restricted common stock, valued at approximately $43,155, in addition to a monthly cash payment of $7,500 for their ongoing services.
Marketing Partnership with Levo Healthcare
Following the collaboration with Veritas, Mangoceuticals established a Marketing Agreement with Levo Healthcare Consulting, Inc. This partnership focuses on digital marketing strategies and includes the issuance of 195,000 restricted shares, which will vest monthly alongside a monthly payment of $6,250. Levo is also set to receive warrants allowing for the purchase of up to 300,000 shares upon reaching specific customer milestones.
Management Consultation with Luca Consulting
A further notable engagement occurred with Luca Consulting, LLC, which was contracted for management consulting services. In return for their expertise, Luca was granted 650,000 shares of restricted common stock valued at around $175,500, alongside a cash payment totaling $30,000 distributed over the six-month agreement.
Utilization of Equity Line of Credit
Mangoceuticals has also efficiently utilized its Equity Line of Credit (ELOC) with Platinum Point Capital, issuing 2,000,000 shares at a price of $0.26 per share. This transaction yielded net proceeds of $521,016 after accounting for associated fees and expenses. Importantly, this endeavor is part of a larger financial strategy involving Platinum Point Capital's commitment to purchase up to $25 million worth of the company's common stock.
Recent Developments and Innovations
Mangoceuticals, also known as MangoRx, has been making headlines with its recent innovations. The company is excited to launch a new weight loss treatment branded as Slim, now available through its telemedicine platform. Moreover, MangoRx secured investment by selling 500 shares of its Series B Convertible Preferred Stock to an institutional accredited investor while simultaneously increasing the monthly car allowance for its CEO, Jacob Cohen.
Patents and Clinical Trials
The company has proudly secured a patent in India for its forward-looking preventive care technology. It has also initiated clinical trials in collaboration with Vipragen Biosciences, striving to enhance healthcare solutions. Notably, MangoRx received DEA authorization for its telemedicine operating system via Surescripts, enabling the prescription of a wider range of medications.
Leadership and Strategic Partnerships
In another testament to its commitment to healthcare advancement, MangoRx welcomed Dr. Douglas Christianson as the new Director of Medical Research and Product Innovation. The company is also forming strategic partnerships, such as one with the International Society of Frontier Life Sciences and Technology, aimed at distributing its men's health and wellness products throughout Asia and Latin America.
Frequently Asked Questions
What recent agreements has Mangoceuticals entered into?
Mangoceuticals has entered into consulting agreements with several firms, including Veritas, Levo Healthcare, and Luca Consulting, paying them partly with equity.
What is the purpose of these consulting agreements?
These agreements are designed to enhance investor relations, digital marketing, and management consulting services, supporting the company's growth strategy.
How is Mangoceuticals utilizing its Equity Line of Credit?
The company has issued shares through its Equity Line of Credit with Platinum Point Capital, part of a broader strategy to raise up to $25 million in common stock purchases.
What innovative products has MangoRx introduced?
MangoRx has launched a new weight loss treatment, Slim, and is developing new technologies and products through various clinical trials and partnerships.
Who has been appointed as the Director of Medical Research at MangoRx?
Dr. Douglas Christianson has been appointed as the new Director of Medical Research and Product Innovation, reinforcing the company's commitment to healthcare improvement.
